Updates from the 30th EADV Congress: Dr. Gurbir Dhadwal reviews efficacy of TYK2 inhibitors, interruptions to secukinumab treatment, and a comparison of bimekizumab and secukinumab in different patient subgroups [Video 8 min]

In this 8-minute video, Dr. Gurbir Dhadwal reviews guidance from the 30th EADV Congress on efficacy of TYK2 inhibitors, interruptions to secukinumab treatment, and a comparison of bimekizumab and secukinumab in different patient subgroups.


>> View the video (en anglais avec sous-titres français) [8 min 27 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.